Simoa is an ultra-sensitive immunoassay technology that allow detection of proteins and nucleic acids at lowest possible levels. It's a simple, flexible, robust, and sensitive multiplex immunoassay platform for measuring biomarkers in most common sample types.
Simoa® Bead Technology presents the ability to detect neurological biomarkers at ultra-low levels, which have traditionally only been detectable in cerebrospinal fluid. The technology has the potential to transform the way brain injuries and diseases are diagnosed.
Simoa assays can detect neurological biomarkers, such as Neurofilament Light (NfL),Tau, GFAP and several others associated with brain injury and disease. With Simoa, these informative markers can be detected at much earlier stages, in blood, serum or plasma, enabling better understanding of the long-term effects and disease pathology without invasive measures.
The digital biomarker detection technology, Simoa®, is changing the way in which the biology of health and disease is studied by giving researchers the ability to examine critical proteins and nucleic acids, at ultra low - even baseline - levels, in most common sample types.
The technology is perfectly suited for single- and multi-plex detection of key biomarkers at ultra-low levels in applications within all therapeutic areas, such as neurology, immunology, infectious disease, cardiology and oncology.
The innovative digital nature of the technique allows an average of 1000 times sensitivity increase over conventional assays, with CVs less than 10 percent.
Incubation time for analyte capture and detector binding is typically about 30 minutes, with five minutes for labeling by the streptavidin β-galactosidase (SBG) conjugate.
View more information on www.quanterix.com/technology
Simoa is a highly sensitive, automated solution that is revolutionizing new discoveries in the biology of health and disease. The Simoa science is based upon the isolation of individual immunocomplexes on paramagnetic beads using standard ELISA reagents.
The main difference between Simoa and conventional immunoassays lies in the ability to trap single molecules in femtoliter-sized wells, allowing for a “digital” readout of each individual bead to determine if it is bound to the target analyte or not. The digital nature of the technique allows an average of 1000 times sensitivity increase over conventional assays with CVs less than 10 percent.